Entera Bio names Riccardo Paolo Camisasca chief medical officer
ENTX•Entera Bio appoints chief medical officer ahead of Phase 3
Entera Bio named Riccardo Paolo Camisasca as chief medical officer ahead of its planned EB613 Phase 3 initiation.
Camisasca most recently served as global head of R&D at Sumitomo Pharma Switzerland, overseeing clinical development and global trial execution.
He previously held clinical development and medical affairs leadership roles at Bial, Syneos Health, Takeda, Novartis.
Related News
CBL International says 1H 2026 profit rebound driven by higher bunker volumes, wider margins amid oil price surge
BANL•
Invesco names Clint Harris global head of Solutions & Custom Strategies platform
IVZ•
